Dapagliflozin's Association With Cardiorenal Outcomes and Apolipoprotein M Levels in HFrEF Patients
Open Access
- 25 June 2025
- journal article
- Published by Elsevier in JACC: Advances
- Vol. 4 (6) , 101800
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca United States
This publication has 25 references indexed in Scilit:
- Albuminuria and Heart FailureJACC, 2023
- Apolipoprotein M Attenuates Anthracycline Cardiotoxicity and Lysosomal InjuryJACC: Basic To Translational Science, 2023
- Apolipoprotein M and its impact on endothelial dysfunction and inflammation in the cardiovascular systemAtherosclerosis, 2021
- Quantitative Proteomic Analysis of Diabetes Mellitus in Heart Failure With Preserved Ejection FractionJACC: Basic To Translational Science, 2021
- Dapagliflozin in Patients with Chronic Kidney DiseaseNew England Journal of Medicine, 2020
- Aging Suppresses Sphingosine-1-Phosphate Chaperone ApoM in Circulation Resulting in Maladaptive Organ RepairDevelopmental Cell, 2020
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2019
- Apolipoprotein M in patients with chronic kidney diseaseAtherosclerosis, 2018
- Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trialThe Lancet Diabetes & Endocrinology, 2017
- Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDLAtherosclerosis, 2012